LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84–90 36.Marre M, Shaw J, Bra ¨ndle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S, LEAD-1 SU StudyGroup 2009 Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improve-ments in glycaemic and weight control compared with addingrosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1SU). Diabet Med 26:268–278 37.Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-weekrandomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39–47 38.Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R2009 Treatment with the human once-weekly glucagon-like pep-